Another one I almost missed...
CD138 is expressed in advanced and aggressive prostate cancers, playing a role in tumor progression and interactions with the microenvironment. Its expression is higher in metastatic disease, making it a potential biomarker for aggressiveness.
QXL138AM is a masked immuno-cytokine (MIC) targeting CD138, a receptor found in prostate cancer and other CD138-expressing tumors. It delivers interferon alpha 2 (IFNα2) directly to the tumor site, enhancing anti-tumor activity while minimizing systemic toxicity through a tumor-selective masking mechanism.
Preclinical studies showed 69% tumor growth inhibition in prostate cancer models, highlighting its potential. QXL138AM has also received FDA Orphan Drug Designation for multiple myeloma and pancreatic cancer.
Currently in Phase 1 clinical trials (NCT06582017) and recruiting participants, the study is assessing its safety, dosing, and early efficacy in patients with CD138-positive cancers, including prostate cancer. This innovative therapy represents a promising option for patients with advanced, hard-to-treat cancers.
Bayer announces positive topline results for NUBEQA® (darolutamide) from Phase III trial in men with mHSPC - July 17, 2024
Strategies to Re-Sensitize Castration-Resistant Prostate Cancer to Antiandrogen Therapy